Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific innovation and advanced manufacturing [2] Group 1: Investment Plans - The investment will enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline for cancer, blood diseases, and autoimmune diseases [3] - This investment follows a previous commitment of up to $2.5 billion to establish a strategic R&D center in Beijing, marking AstraZeneca's sixth global and second Chinese R&D center [2] Group 2: R&D and Innovation - As of January 2023, AstraZeneca has invested over $1.8 billion in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - The company currently has over 200 projects in its Chinese R&D pipeline, with 10-15 new projects added annually [3] Group 3: Strategic Importance - AstraZeneca's CEO emphasized that this investment marks a new chapter in the company's development in China, recognizing the country's role in scientific innovation and global public health [2]

2026.01. 29 本文字数：898，阅读时长大约2分钟 作者 | 第一财经 钱童心 1月29日，在英国首相斯塔默访华期间，阿斯利康宣布，计划于2030年前在中国投资超过1000亿元 人民币，以扩大在药品生产与研发领域的布局。 这也是这家英国制药巨头对中国市场作出的最新承诺。公司称，最新的投资将充分发挥中国的科研优 势和先进制造能力，并依托中英医疗健康生态系统之间的协同合作，为中国及全球患者带来前沿创新 疗法。 去年3月，阿斯利康宣布了一项价值高达25亿美元的投资计划，将在北京建立全球第六个、中国第二 个战略研发中心，并达成多项重大研发与生产合作，以进一步推动中国生命科学事业发展。 阿斯利康全球首席执行官苏博科表示："今天宣布的这笔超过1000亿元人民币的重大投资，开启了 阿斯利康在华发展的新篇章。中国已成为科学创新、先进制造和全球公共卫生领域的重要力量。通过 进一步扩展我们在细胞治疗、放射偶联药物等突破性疗法的能力，阿斯利康将为中国高质量发展作出 更大贡献，更重要的是，把下一代创新疗法带给更多患者。" 中国在新疗法领域拥有前沿科学。据介绍，这些投资将覆盖从药物发现、临床开发到生产制造的完整 价值链，将中 ...

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to enhance its drug production and R&D capabilities, leveraging China's scientific research strengths and advanced manufacturing [1][3] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, aiming to bring China's innovative results to a global audience [3] - AstraZeneca's CEO highlighted that this investment marks a new chapter in the company's development in China, recognizing the country as a significant force in scientific innovation and global public health [3] Group 2: Strategic Initiatives - The investment will significantly enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline that benefits patients with cancer, blood diseases, and autoimmune disorders [3] - AstraZeneca aims to become the first multinational pharmaceutical company with end-to-end cell therapy capabilities in China [3] Group 3: Previous Investments - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - As of January this year, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [3]